American Association for Clinical Chemistry
Better health through laboratory medicine
Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers
 

  The National Academy of Clinical Biochemistry
Laboratory Medicine Practice Guidelines
Use of Tumor Markers in
Liver, Bladder, Cervical, and Gastric Cancers

Published Guidelines
Access to Table of Contents

We present here to clinical chemists, clinicians and other practitioners of laboratory and clinical medicine the latest update of the national Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumor markers in liver, bladder, cervical, lung and gastric cancers. These guidelines are intended to encourage more appropriate use of tumor marker tests by primary care physicians, hospital physicians and surgeons, specialist oncologists, and other health professionals.

Committee (Author) Disclosures  

NACB Committee Members:

Catharine M. Sturgeon
Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK

Michael J. Duffy
Department of Pathology and Laboratory Medicine, St Vincent’s University Hospital and UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland

Barry R. Hoffman
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada

Rolf Lamerz
Department of Medicine, Klinikum of the University Munich, Grosshadern, Germany

Herbert A. Fritsche

Department of Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Katja Gaarenstroom

Department of Gynecology, Leiden University Medical Center, Leiden, the Netherlands

Johannes M.G Bonfrer

Department of Clinical Chemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands

Thorsten Ecke

Department of Urology, Helios Hospital, Bad Saarow, Germany

 H. Barton Grossman

Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Peter Hayes

Scottish Liver Transplant Unit, Department of Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

Ralf-Thorsten Hoffmann

Department of Clinical Radiology, LMU-Klinikum-Grosshadern, University of Munich, Germany

Seth P. Lerner

Department of Urology, Baylor College of Medicine, Houston, TX

Florian Lohe

Department of Surgery, LMU-Klinikum-Grosshadern, University of Munich, Germany

Johanna Louhimo

Department of Clinical Chemistry, Helsinki University Central Hospital, Finland

Ihor Sawczuk

Department of Urology, Hackensack University Medical Center, Hackensack,NJ

Kazuhisa Taketa

Clinical Trial Center, Brain Attack Center, Oota Memorial Hospital, Fukuyama, Japan

Eleftherios P. Diamandis
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada

This LMPG was developed by an independent committee of the NACB. Subsequent publication of these guidelines has been supported by the Academy.